• Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients with relapsed/refractory peripheral and cutaneous T cell lymphoma.

• The Tenalisib and Romidepsin combination was well tolerated with overall safety profile comparable to that of individual agents.

• The combination has showed encouraging signals of efficacy in patients who have failed multiple lines of prior therapies

• The company expects that the final results of the study will support a pivotal trial for the combination and plans to seek FDA feedback on its strategy once the full results are available.

LA CHAUX DU FONDS, Switzerland-Sunday 6 December 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refract ... Read more »

 Citi Private Bank expects that 2021 will mark the beginning of a new economic cycle, one that has more powerful tailwinds than investors expect. It is a time to be fully invested and hopeful.

NEW YORK-Saturday 5 December 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors.

Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global he ... Read more »